Chemical structural formula and molecular formula analysis of Brivaracetam

Brivaracetam is an oral antiepileptic drug used to treat partial-onset epilepsy in patients 1 month of age and older. Its chemical name is (2S)-2-[(4R)-2-oxo-4-propyltetrahydro-1H-pyrrol-1-yl]butanamide, its molecular formula is C11H20N2O2, and its molecular weight is 212.29. Brivaracetam's structural characteristics allow it to play specific roles in the nervous system and help control epileptic seizures.

From a chemical structure perspective, the core structure of Brivaracetam is a compound containing a pyrrole ring. Its structure contains a tetrahydropyrrole ring with an oxo group connected to the top of the ring; this part is a unique structural feature of brivaracetam. Unlike traditional anti-epileptic drugs, brivaracetam shows good efficacy by selectively binding to synaptic vesicle protein 2A (SV2A), regulating the release of neurotransmitters, thereby reducing the frequency of epileptic seizures.

Brivaracetam is a white to off-white crystalline powder whose physical properties give it certain advantages in drug development. The drug is readily soluble in water, buffers (pH 1.2, 4.5 and 7.4), ethanol, methanol and glacial acetic acid, which means it is easily absorbed and works during the formulation process. In addition, brivaracetam also shows good solubility in certain organic solvents such as toluene, and is slightly soluble in n-hexane. This property is essential for its preparation in oral administration form.

In the development and application of drugs, the chemical properties and biocompatibility of brivaracetam deserve attention. Its relatively low toxicity and high therapeutic index make it a safe and effective option in the treatment of epilepsy. In addition, due to the complex molecular structure of brivaracetam, its synthesis process needs to be strictly controlled to ensure the purity and stability of the drug.

Reference materials:https://www.briviact.com/